Can a new drug ease the dryness, pain, and fatigue of Sjögren's disease?

NCT ID NCT07737743

Not yet recruiting Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether an experimental drug called DDY391 can reduce disease activity and improve symptoms like dryness, pain, and fatigue in people with Sjögren's disease. About 344 participants will receive either DDY391 at one of three dose levels or a placebo for up to 52 weeks. The study aims to see if DDY391 can help control this autoimmune condition and to determine the best dose for future testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called DDY391
What this could lead to: If DDY391 works, it could offer a new treatment option to reduce disease activity and improve daily symptoms like dryness, pain, and fatigue in people with Sjögren's disease.
What could go wrong: This is a mid-stage trial, so DDY391 may not prove effective or safe enough to move forward. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJÖGREN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJÖGREN'S DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.